Appendix 1. Prediction of mortality
The models estimate individual patient mortality by adjusting background mortality hazards number of deaths as well as numbers at risk at yearly intervals. These were processed to generate virtual patient-level data by assigning death or alive (i.e. censored) status at each age based on the available counts for each cohort.
The data were analyzed to test various parametric distributions; these included the exponential, Weibull, Gompertz, log-normal, gamma, and log-logistic. The optimal parametric fit was selected based on statistical fit (Akaike Information Criterion and the Bayesian Information Criterion, closeness of fit in comparisons of observed and predicted curves), as well as based on the clinical plausibility of fits (based on median survival times, and shape of projected curves).
Data from each of the birth cohort groups were first analyzed separately to assess the possibility of accurate fitting in the most recent cohorts (e.g. 2007 to 2011), as these are more reflective of current survival expectations. Follow-up in these groups was very short with curves dropping by a few percent only, which led to projections of implausibly long survival. Thus, the birth cohorts were grouped in order to overcome this issue. The final analyses were based on survival data from the 1992 to 2011 cohorts (Appendix 1 Figure   1 ). the curve reaching 0% near 65 years of age, and a predicted median of 39.7 years (Appendix 1 Figure 1 , Appendix 1 Table 1 ). The survival of birth cohorts for 2012 and after were not updated in the US CFFPR reports published after 2011; therefore, they were not included in the fitting exercise. The Gompertz survival function used in the model is shown below: The probability of death at each cycle in the survival model (p) is calculated using the following formula:
Where h is the annual mortality hazard calculated at that cycle and t is the cycle length (in years). Random numbers are used to determine in which cycle an individual patient would die. After death, the patient exits the model and the next patient is simulated through the model. lumacaftor/ivacaftor to a matched control cohort from the US CFFPR (13), the model assumed that while a patient was receiving lumacaftor/ivacaftor + SC, they had a 42%
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slower annual rate of decline in ppFEV1.
PEx rate
Occurrence of PEx per patient in each model cycle was predicted contingent on patient ppFEV1 and age from a relationship derived from the 2004 US CFFPR, based on a publication by Goss et al. 2007 (32) . PEx rates were found to increase with lower ppFEV1.
The data reported were fitted to an exponential regression function, to provide a continuous relationship between the PEx rates and ppFEV1 (24) .
PEx rate = a*exp(-b*ppFEV1)
Two equations were applied: for patients aged < 18 years (a = 8.594, b =0 .035), and ≥ 18 years (a = 3.789, b = 0.026). Since the PEx events tracked in this data source were likely those that were treated with intravenous antibiotics and/or hospitalization, it is this subset of PEx that is tracked in the model.
For patients aged 6 to 11 years, no treatment effect of lumacaftor/ivacaftor + SC was assumed on PEx, as the 809-109 study was not powered to detect a difference in PEx rate.
For patients aged ≥ 12 years, lumacaftor/ivacaftor + SC treatment was assumed to reduce the rate by 56%, the observed treatment effect on the rate of PExs treated with intravenous antibiotics from TRAFFIC/TRANSPORT study (10).
Weight-for-age z-score
During the first 2 years of the simulation, patients on lumacaftor/ivacaftor + SC were assumed to experience a constant weight-for-age z-score increase of 0.033 per year based on the findings from the registry-matched analysis by Konstan et al. (13) . Patients on SC alone declined by 0.030 per year for the first two years after baseline (13). Weight-for-age zscore was updated during the first 2 years of treatment and was subsequently assumed to remain constant over time.
Lung transplantation
International guidelines suggest that patients with CF and a ppFEV1 of < 30% should be evaluated for lung transplantation (31) . Thus, in the model, patients were assumed to be eligible to receive a lung transplant when ppFEV1 fell below 30%. The percentage of eligible patients who went on to receive a transplant was estimated to be 26.8%, based on data from the 2015 US CFFPR report (2) , this was implemented in the model as a one-time chance (26.8% risk) of receiving a lung transplant once ppFEV1 fell below 30%.
Lumacaftor/ivacaftor discontinuation
Discontinuation rates for Weeks 1 to 24 of the simulation were derived from discontinuation data from either (i) TRAFFIC/TRANSPORT for patients who were aged ≥ 12 years at baseline, or (ii) the 809-109 study for patients aged 6 to 11 years at baseline. The discontinuation rate for Weeks 25 to 96 was based on the discontinuation from the first 72 weeks of the PROGRESS study (13) . While PROGRESS only included patients aged ≥ 12 years who completed TRAFFIC/TRANSPORT, the model assumed these data were applicable for patients aged ≥ 6 years in the absence of longer-term lumacaftor/ivacaftor discontinuation data for patients aged 6 to 11 years. Patients who discontinued lumacaftor/ivacaftor during the first 24 weeks of the model were assumed to retain the acute increase in ppFEV1, as the ppFEV1 treatment effect was derived from an intent-to-treat analysis and so included patients who discontinued. In contrast, for patients who discontinued lumacaftor/ivacaftor between in Weeks 25 to 96, the acute ppFEV1 increase was removed in the cycle in which the patient discontinues. The model assumed no discontinuation of lumacaftor/ivacaftor after 96 weeks. Upon discontinuation of lumacaftor/ivacaftor, a patient was assumed to transition to SC alone. 
Appendix 4. Probabilistic sensitivity analysis (PSA)
A PSA was conducted to account for multivariate and stochastic uncertainty in the model.
The PSA tests effect of statistical uncertainty of model parameters on model outcomes. The uncertainty in the individual parameters was characterized using probability distributions and analyzed using Monte Carlo simulation (1,000 replications). In the PSA, the uncertainties around parameters were estimated as shown in Appendix 4 
